Zobrazeno 1 - 10
of 177
pro vyhledávání: '"daprodustat"'
Autor:
Guoying Tai, Fangming Xia, Cathy Chen, Adrian Pereira, Jill Pirhalla, Xiusheng Miao, Graeme Young, Claire Beaumont, Liangfu Chen
Publikováno v:
Pharmacology Research & Perspectives, Vol 11, Iss 6, Pp n/a-n/a (2023)
Abstract Daprodustat is an oral small molecule hypoxia‐inducible factor (HIF) prolyl hydroxylase inhibitor (PHI) approved in Japan and the United States for the treatment of anemia associated with chronic kidney disease. This phase 1, nonrandomized
Externí odkaz:
https://doaj.org/article/a382a4b8717a4911bae8d4c3e4e188aa
Autor:
Takashi Iso, Yuya Matsue, Akira Mizukami, Takashi Tokano, Kikuo Isoda, Satoru Suwa, Katsumi Miyauchi, Naotake Yanagisawa, Yasuo Okumura, Tohru Minamino
Publikováno v:
ESC Heart Failure, Vol 9, Iss 6, Pp 4291-4297 (2022)
Abstract Aims Hypoxia‐inducible factor‐prolyl hydroxylase (HIF‐PH) inhibitors have been developed for the treatment of renal anaemia; however, no study has evaluated the safety and efficacy of HIF‐PH inhibitors in patients with heart failure
Externí odkaz:
https://doaj.org/article/deed0b6dfb234429bc28dbbc2b31dc89
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
The United States FDA has approved daprodustat (DPD) as the first oral treatment option for anemia due to chronic kidney disease (CKD) in dialysis patients. Clinical trials have demonstrated DPD’s efficacy and safety, showing non-inferiority to dar
Externí odkaz:
https://doaj.org/article/abdd093a06154bc29e5fc2c97cb94e95
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Introduction: Daprodustat, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI), its efficacy and safety remain unclear. Thus, we conducted this meta-analysis aiming at investigating its efficacy and safety on the treatment of pati
Externí odkaz:
https://doaj.org/article/9c9a49c6d16e4f89b563467696df1ee3
Autor:
Andrea Tóth, Dávid Máté Csiki, Béla Nagy, Enikő Balogh, Gréta Lente, Haneen Ababneh, Árpád Szöőr, Viktória Jeney
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Aims: Chronic kidney disease (CKD) is frequently associated with other chronic diseases including anemia. Daprodustat (DPD) is a prolyl hydroxylase inhibitor, a member of a family of those new generation drugs that increase erythropoiesis via activat
Externí odkaz:
https://doaj.org/article/1b36c0396d4b4845b4eb5c680dbc9143
Autor:
Mengqiu Miao, Mengqiu Wu, Yuting Li, Lingge Zhang, Qianqian Jin, Jiaojiao Fan, Xinyue Xu, Ran Gu, Haiping Hao, Aihua Zhang, Zhanjun Jia
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Hypoxia inducible factors (HIFs) and their regulatory hydroxylases the prolyl hydroxylase domain enzymes (PHDs) are the key mediators of the cellular response to hypoxia. HIFs are normally hydroxylated by PHDs and degraded, while under hypoxia, PHDs
Externí odkaz:
https://doaj.org/article/c2a096005a2e4107870d1a9d57878851
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Qiyan Zheng, Yahui Wang, Huisheng Yang, Luying Sun, Xinwen Fu, Ruojun Wei, Yu Ning Liu, Wei Jing Liu
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2021)
Objective: Daprodustat is a novel oral agent in treating anemia of chronic kidney disease (CKD), and several clinical trials have been conducted to compare daprodustat with recombinant human erythropoietin (rhEPO) or placebo. Our systematic review ai
Externí odkaz:
https://doaj.org/article/8be323a3549843c49573adcd04f6132d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.